CDK1 interacts with rar? and plays an important role in treatment response of acute myeloid leukemia

Cell Cycle

Volumn 12, Issue 8, 2013, Pages 1251-1266

  Hedblom, Andreas ^a   Laursen, Kristian B ^b   Miftakhova, Regina ^a   Sarwar, Martuza ^a   Anagnostaki, Lola ^c   Bredberg, Anders ^c   Mongan, Nigel P ^d   Gudas, Lorraine J ^b   Persson, Jenny L ^a  

^a Clinical Research Center   (Sweden)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

AML; CDK1; Cell cycle; Differentiation; Leukemia; Retinoic acid receptor; Therapy

Indexed keywords

CYCLIN A2; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; MESSENGER RNA; PROTEIN KINASE B; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL STRAIN U937; CELL SURVIVAL; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COMPLEX FORMATION; DIFFERENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MITOSIS RATE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; REGULATORY MECHANISM; TREATMENT RESPONSE;

EID: 84876244657     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.24313     Document Type: Article

References (39)

1. Ofran Y, Rowe JM. Treatment for relapsed acute myeloid leukemia: What is new? Curr Opin Hematol 2012; 19:89-94; PMID:22227525; http://dx.doi.org/10.1097/ MOH.0b013e32834ff4e1
2. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009; 9:153-66; PMID:19238148; http://dx.doi.org/10. 1038/nrc2602
3. Santamaría D, Barrière C, Cerqueira A, Hunt S, Tardy C, Newton K, et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007; 448:811-5; PMID:17700700; http://dx.doi.org/10.1038/nature06046
4. Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, et al. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS ONE 2011; 6:e23849; PMID:21887332; http://dx.doi.org/10.1371/journal.pone.0023849
5. Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, et al. Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer. Br J Cancer 2012; 106:133-40; PMID:22108518; http://dx.doi.org/10.1038/bjc.2011.504
6. Kim SJ, Nakayama S, Miyoshi Y, Taguchi T, Tamaki Y, Matsushima T, et al. Determination of the specific activity of CDK1 and CDK2 as a novel prognostic indicator for early breast cancer. Ann Oncol 2008; 19:68-72; PMID:17956886; http://dx.doi.org/10.1093/annonc/mdm358
7. Gavet O, Pines J. Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell 2010; 18:533-43; PMID:20412769; http://dx.doi.org/10. 1016/j.devcel.2010.02.013
8. Borriello A, Cucciolla V, Criscuolo M, Indaco S, Oliva A, Giovane A, et al. Retinoic acid induces p27Kip1 nuclear accumulation by modulating its phosphorylation. Cancer Res 2006; 66:4240-8; PMID:16618747; http://dx.doi.org/ 10.1158/0008-5472.CAN-05-2759
9. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol 1995; 6:63-72; PMID:7647308; http://dx.doi.org/10.1006/scbi.1995.0009
10. Borgne A, Meijer L. Sequential dephosphorylation of p34(cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. J Biol Chem 1996; 271:27847-54; PMID:8910383; http://dx.doi.org/10.1074/jbc.271.44.27847
11. Charrier-Savournin FB, Château MT, Gire V, Sedivy J, Piette J, Dulic V. p21-Mediated nuclear retention of cyclin B1-Cdk1 in response to genotoxic stress. Mol Biol Cell 2004; 15:3965-76; PMID:15181148; http://dx.doi.org/10.1091/mbc.E03-12-0871
12. Kõivomägi M, Valk E, Venta R, Iofik A, Lepiku M, Morgan DO, et al. Dynamics of Cdk1 substrate specificity during the cell cycle. Mol Cell 2011; 42:610-23; PMID:21658602; http://dx.doi.org/10.1016/j.molcel. 2011.05.016
13. Queralt E, Uhlmann F. Cdk-counteracting phosphatases unlock mitotic exit. Curr Opin Cell Biol 2008; 20:661-8; PMID:18845253; http://dx.doi.org/10.1016/j. ceb.2008.09.003
14. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-83; PMID:16603719; http://dx.doi.org/10. 1200/JCO.2005.03.7689
15. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol 2011; 29:495-503; PMID:21220600; http://dx.doi.org/10. 1200/JCO.2010.32.1067
16. Lamkin TJ, Chin V, Yen A. All-trans retinoic acid induces p62DOK1 and p56DOK2 expression which enhances induced differentiation and G0 arrest of HL-60 leukemia cells. Am J Hematol 2006; 81:603-15; PMID:16823827; http://dx.doi.org/10.1002/ajh.20667
17. Wang J, Barsky LW, Shum CH, Jong A, Weinberg KI, Collins SJ, et al. Retinoid-induced G1 arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha. J Biol Chem 2002; 277:43369-76; PMID:12213824; http://dx.doi.org/10.1074/jbc.M206792200
18. David KA, Mongan NP, Smith C, Gudas LJ, Nanus DM. Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther 2010; 9:678-84; PMID:20200483; http://dx.doi.org/10.4161/cbt.9.9.11436
19. Dimberg A, Oberg F. Retinoic acid-induced cell cycle arrest of human myeloid cell lines. Leuk Lymphoma 2003; 44:1641-50; PMID:14692514; http://dx.doi.org/10.1080/1042819031000083316
20. Suzui M, Shimizu M, Masuda M, Lim JT, Yoshimi N, Weinstein IB. Acyclic retinoid activates retinoic acid receptor beta and induces transcriptional activation of p21(CIP1) in HepG2 human hepatoma cells. Mol Cancer Ther 2004; 3:309-16; PMID:15026551
21. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011; 6:345-64; PMID:21073338; http://dx.doi.org/10.1146/ annurevpathol-011110-130303
22. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006; 58:760-72; PMID:17132853; http://dx.doi.org/10.1124/pr.58.4.7
23. Bour G, Lalevée S, Rochette-Egly C. Protein kinases and the proteasome join in the combinatorial control of transcription by nuclear retinoic acid receptors. Trends Cell Biol 2007; 17:302-9; PMID:17467991; http://dx.doi.org/10.1016/j.tcb.2007.04.003
24. Duong V, Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim Biophys Acta 2011; 1812:1023-31; PMID:20970498; http://dx.doi.org/10.1016/j.bbadis. 2010.10.007
25. Ekberg J, Holm C, Jalili S, Richter J, Anagnostaki L, Landberg G, et al. Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome. Eur J Haematol 2005; 75:106-15; PMID:16004607; http://dx.doi.org/10.1111/j.1600-0609.2005.00473.x
26. Boylan JF, Lufkin T, Achkar CC, Taneja R, Chambon P, Gudas LJ. Targeted disruption of retinoic acid receptor alpha (RAR alpha) and RAR gamma results in receptor-specific alterations in retinoic acid-mediated differentiation and retinoic acid metabolism. Mol Cell Biol 1995; 15:843-51; PMID:7823950
27. Laursen KB, Wong PM, Gudas LJ. Epigenetic regulation by RAR{alpha} maintains ligand-independent transcriptional activity. Nucleic Acids Res 2012; 40:102-15; PMID:21911359
28. Ekberg J, Landberg G, Holm C, Richter J, Wolgemuth DJ, Persson JL. Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells. Oncogene 2004; 23:9082-9; PMID:15489899; http://dx.doi.org/10.1038/sj.onc.1208090
29. Hsieh FF, Barnett LA, Green WF, Freedman K, Matushansky I, Skoultchi AI, et al. Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase. Blood 2000; 96:2746-54; PMID:11023508
30. Giannì M, Bauer A, Garattini E, Chambon P, Rochette-Egly C. Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation. EMBO J 2002; 21:3760-9; PMID:12110588; http://dx.doi.org/10.1093/emboj/cdf374
31. Lovat PE, Annicchiarico-Petruzzelli M, Corazzari M, Dobson MG, Malcolm AJ, Pearson AD, et al. Differential effects of retinoic acid isomers on the expression of nuclear receptor co-regulators in neuroblastoma. FEBS Lett 1999; 445:415-9; PMID:10094499; http://dx.doi.org/10.1016/S0014-5793(99)00162-3
32. Minucci S, Pelicci PG. Retinoid receptors in health and disease: Co-regulators and the chromatin connection. Semin Cell Dev Biol 1999; 10:215-25; PMID:10441075; http://dx.doi.org/10.1006/scdb.1999.0303
33. Li R, Faria TN, Boehm M, Nabel EG, Gudas LJ. Retinoic acid causes cell growth arrest and an increase in p27 in F9 wild type but not in F9 retinoic acid receptor beta2 knockout cells. Exp Cell Res 2004; 294:290-300; PMID:14980522; http://dx.doi.org/10.1016/j.yexcr.2003.11.014
34. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: Key players? Good targets? Nat Rev Cancer 2007; 7:495-507; PMID:17568790; http://dx.doi.org/10.1038/nrc2169
35. Radomska HS, Alberich-Jordà M, Will B, Gonzalez D, Delwel R, Tenen DG. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα. J Clin Invest 2012; 122:2955-66; PMID:22797303; http://dx.doi.org/10.1172/JCI43354
36. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003; 13:1775-85; PMID:14561402; http://dx.doi.org/10. 1016/j.cub.2003.09.024
37. Ortega S, Prieto I, Odajima J, Martín A, Dubus P, Sotillo R, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003; 35:25-31; PMID:12923533; http://dx.doi.org/10. 1038/ng1232
38. Bailly E, Dorée M, Nurse P, Bornens M. p34cdc2 is located in both nucleus and cytoplasm; part is centrosomally associated at G2/M and enters vesicles at anaphase. EMBO J 1989; 8:3985-95; PMID:2686978
39. Bailly E, Pines J, Hunter T, Bornens M. Cytoplasmic accumulation of cyclin B1 in human cells: Association with a detergent-resistant compartment and with the centrosome. J Cell Sci 1992; 101:529-45; PMID:1387877